Mechanisms of chemotherapy resistance in ovarian cancer
Mylena Ortiz, Emma Wabel, Kerry Mitchell, Sachi Horibata
Abstract
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.
Topics & Concepts
Ovarian cancerOlaparibBevacizumabMedicinePaclitaxelChemotherapyOncologyInternal medicineVascular endothelial growth factorDrug resistanceCancer researchPharmacologyCancerPoly ADP ribose polymerasePolymeraseVEGF receptorsBiologyDNAMicrobiologyGeneticsPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies